LTS Lohmann Therapie-Systeme Competitors and Similar CompaniesClear all

LTS Lohmann Therapie-Systeme's competitors and similar companies include Porton Biopharma, Lepu Biopharma, Esteve and Teva Pharmaceuticals.

	LTS Lohmann Therapie-Systeme LTS Lohmann Therapie-Systeme develops and manufactures transdermal drug delivery systems for pharmaceutical active substances.	Porton Biopharma Porton Biopharma is a pharmaceutical development and manufacturing company.	Lepu Biopharma Lepu Biopharma is a biopharmaceutical company that focuses on oncology therapeutics.	Esteve Esteve is a company that manufactures and supplies pharmaceuticals.	Teva Pharmaceuticals Teva Pharmaceuticals is a global pharmaceutical company.
Founding Date	Founding Date 1984	Founding Date 2015	Founding Date 2018	Founding Date 1929	Founding Date 1901
Type	Type Subsidiary	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy
Locations	Locations Andernach, DE HQ Shanghai, CN West Caldwell, US	Locations Salisbury, GB HQ Salisbury, GB Selby, GB	Locations HK HQ	Locations Barcelona, ES HQ Shaoxing, CN Paris, FR Berlin, DE Milan, IT Lisbon, PT Barcelona, ES see more	Locations Petah Tikva, IL HQ Villa Adelina, AR Macquarie Park, AU Minsk, BY Antwerpen, BE Sao Paulo, BR Dupnica, BG see more
Employees	Employees 2991% increase	Employees 1462% decrease	Employees 498	Employees 2,0063% increase	Employees 37,000
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥934.9m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $17.3b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥89.6m (FY, 2025)	Cost of goods N/A	Cost of goods $8.3b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ¥852.5m (FY, 2025)	Gross profit N/A	Gross profit $8.9b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income ¥258.9m (FY, 2025)	Net income N/A	Net income $1.4b (FY, 2025)